Compare Inovio Pharmaceuticals Inc (INO) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Mondaycom Ltd — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Mondaycom Ltd trades at $88.96 (market cap $3.76B). The key difference: Mondaycom Ltd is far larger — about 33.5× Inovio Pharmaceuticals Inc's market cap, and Mondaycom Ltd is more actively traded (836,200 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Mondaycom Ltd for 16 Days on average.
| INO | MNDY | |
|---|---|---|
Market Cap | $112.19M | $3.76B |
Volume | 3,201,278 | 836,200 |
Sector | Health | Technology |
52-Week High | $2.65 | $205.24 |
52-Week Low | $0.66 | $58.81 |
Typical Hold Time | 43 Days | 16 Days |
Enterprise Value | $83.51M | $2.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Monday.com (MNDY) trades at $88.91, up 6.47% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth to $1.23B in 2025, net income of $118.74M, and consistent earnings beats. Recent news highlights AI integration at Elevate '26 conference and inclusion in growth stock lists. Analyst consensus remains strongly bullish with 17 buy ratings and $108.64 price target.
Outlook remains positive given strong enterprise client growth and AI adoption, though elevated valuation ratios (P/E 37.69) and competitive pressures from Meta's enterprise push present risks. The stock offers growth potential but requires monitoring of profit margin sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
